Abstract
Skin and soft tissue infections (SSTIs) are a common cause of hospital admission among elderly patients, and traditionally have been divided into complicated and uncomplicated SSTIs. In 2010, the FDA provided a new classification of these infections, and a new category of disease, named acute bacterial skin and skin structure infections (ABSSSIs), has been proposed as an independent clinical entity. ABSSSIs include three entities: cellulitis and erysipelas, wound infections, and major cutaneous abscesses This paper revises the epidemiology of SSTIs and ABSSSIs with regard to etiologies, diagnostic techniques, and clinical presentation in the hospital settings. Particular attention is owed to frail patients with multiple comorbidities and underlying significant disease states, hospitalized on internal medicine wards or residing in nursing homes, who appear to be at increased risk of infection due to multi-drug resistant pathogens and treatment failures. Management of ABSSSIs and SSTIs, including evaluation of the hemodynamic state, surgical intervention and treatment with appropriate antibiotic therapy are extensively discussed.
Similar content being viewed by others
References
FDA Uncomplicated and Complicated Skin and Skin Structure Infections—Developing Antimicrobial Drugs for Treatment (1998). Available at: http://www.fda.gov/ohrms/dockets/98fr/2566dft.pdf. Accessed 8 Apr 2016
FDA Guideline ABSSSI (2013). Available at: http://www.fda.gov/downloads/Drugs/…/Guidances/ucm071185.pdf. Accessed Sept 2015
Mims C, Playfair J, Roitt I et al. Medical microbiology. Mosby Int Ltd, London. ISBN 0 7234 2781 X
Cutting KF, White R (2004) Defined and refined: criteria for identifying wound infection revisited. Br J Community Nurs 9:S6–S15
Quirke M, Wakai A (2015) Treatment outcome measures for randomized controlled trials of antibiotic treatment for acute bacterial skin and skin structure infections in the emergency department setting. Int J Emerg Med 8:11
Wilson SE, Solomkin JS, Le V, Cammarata SK, Bruss JB (2003) A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid. Am J Surg 185:369–375
Sader HS, Farrell DJ, Jones RN (2010) Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres. Int J Antimicrob Agents 36:28–32
Itani KM, Merchant S, Lin SJ et al (2011) Outcomes and management costs in patients hospitalized for skin and skin-structure infections. Am J Infect Control 39:42–49
Edelsberg J, Taneja C, Zervos M (2009) Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis 15:1516–1518
Miller LG, Eisenberg DF, Liu H et al (2015) Incidence of skin and soft tissue infections in ambulatory and inpatient settings, 2005–2010. BMC Infect Dis 15:362
Cardona AF, Wilson SE (2015) Skin and soft-tissue infections: a critical review and the role of telavancin in their treatment. Clin Infect Dis 61(Suppl 2):S69–S78
Dryden M (2008) Complicated skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus: epidemiology, risk factors, and presentation. Surg Infect (Larchmt) 9(suppl 1):S3–S10
Jeng A, Beheshti M, Li J, Nathan R (2010) The role of beta-hemolytic streptococci in causing diffuse, nonculturable cellulitis: a prospective investigation. Medicine (Baltimore) 89:217–226
Zervos MJ, Freeman K, Vo L et al (2012) Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients. J Clin Microbiol 50:238–245
File TM, Solomkin JS, Cosgrove SE (2011) Strategies for improving antimicrobial use and the role of antimicrobial stewardship programs. Clin Infect Dis 53(Suppl 1):S15–S22
Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) (2013). Available at http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2013.pdf. Accessed 8 Apr 2016
Falcone M, Serra P, Venditti M (2009) Serious infections due to methicillin-resistant Staphylococcus aureus: an evolving challenge for physicians. Eur J Intern Med 20:343–347
Orsi GB, Falcone M, Venditti M (2011) Surveillance and management of multidrug-resistant microrganisms. Expert Rev Anti Infect Ther 9:653–679
Moran GJ, Krishnadasan A, Gorwitz RJ, EMERGEncy ID Net Study Group et al (2006) Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355:666–674
Falcone M, Venditti M (2012) Community-acquired MRSA: a potentially dangerous but invisible enemy. Miner Anestesiol 78:865–867
Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR (2007) Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998–2004). Diagn Microbiol Infect Dis 57:7–13
Tinelli M, Mannino S, Lucchi S et al (2011) Healthcare-acquired infections in rehabilitation units of the Lombardy Region, Italy. Infection 39:353–358
Migliavacca R, Nucleo E, D’Andrea MM et al (2007) Acquired AmpC type beta-lactamases: an emerging problem in Italian long-term care and rehabilitation facilities. New Microbiol 30:295–298
Stevens DL, Bisno AL, Chambers HF et al (2014) Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 59:e10–e52
Falcone M, Blasi F, Menichetti F, Pea F, Violi F (2012) Pneumonia in frail older patients: an up to date. Intern Emerg Med 7:415–424
Rockwood K, Stadnyk K, Carver D et al (2000) A clinimetric evaluation of specialized geriatric care for rural dwelling, frail older people. J Am Geriatr Soc 48:1080–1085
Studio Epidemiologico Longitudinale sull’Invecchiamento (ILSA). http://www.italz.it/CNRPFINV/ilsa.htm. Accessed 8 Apr 2016
Marwick C, Santiago VH, McCowan C, Broomhall J, Davey P (2013) Community acquired infections in older patients admitted to hospital from care homes versus the community: cohort study of microbiology and outcomes. BMC Geriatrics 13:12
Ostermann H, Blasi F, Medina J et al (2014) Resource use in patients hospitalized with complicated skin and soft skin infections in Europe and analysis of vulnerable groups: the REACH study. J Med Econ 17:719–729
Nobili A, Licata G, Salerno F et al (2011) Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol 67:507–519
Nobili A, Marengoni A, Tettamanti M et al (2011) Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. Eur J Intern Med 22:597–602
Liu C, Bayer A, Cosgrove SE et al (2011) Clinical practice guidelines by infectious disease society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52:e18–e55
Harbarth S, Sax H, Fankhauser-Rodriguez C et al (2006) Evaluating the probability of previously unknown carriage of MRSA at hospital admission. Am J Med 119:275 (e15–23)
Zervos M, Freeman K, Vo L et al (2012) Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients. J Clin Microb 50:238–245
Garau J, Blasi F, Medina J, McBride K, Ostermann H, REACH study group (2015) Early response to antibiotic treatment in European patients hospitalized with complicated skin and soft tissue infections: analysis of the REACH study. BMC Infect Dis 15:78
Aliberti S, Giuliani F, Ramirez J, Blasi F (2015) How to choose the duration of antibiotic therapy in patients with pneumonia. Curr Opin Infect Dis 28:177–184
Falcone M, Russo A, Pompeo ME et al (2012) Retrospective case-control analysis of patients with staphylococcal infections receiving daptomycin or glycopeptide therapy. Int J Antimicrob Agents 39:64–68
Eckmann C, Lawson W, Nathwani D et al (2014) Antibiotic treatment pattern across Europe in patients with complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria. Int J Antimicrob Agents 44:56–64
Parodi S, Rhew DC, Goetz MB (2003) Early switch and early discharge opportunities in intravenous vancomycin treatment of suspected methicillin-resistant staphylococcal species infections. J Manag Care Pharm 9:317–326
Liu C, Bayer A, Cosgrove SE, Infectious Diseases Society of America et al (2011) Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52:e18–e55
Levine DP, Fromm BS, Reddy BR (1991) Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 115:674–680
Chang FY, Peacock JE Jr, Musher DM et al (2003) Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 82:333–339
Roberts JA, Taccone FS, Udy AA et al (2011) Vancomycin dosing in critically ill patients. Antimicrob Agents Chemother 55:2704–2709
Patel N, Pai MP, Rodvold KA et al (2011) Vancomycin: we can’t get there from here. Clin Infect Dis 52:969–974
Shaw KJ, Barbachyn MR (2011) The oxazolidinones: past, present, and future. Ann N Y Acad Sci 1241:48–70
Arbeit RD, Maki D, Tally FB, Campanaro E, Eisenstein BI, Daptomycin 98-01 and 99-01 Investigators (2004) The safety and efficacy of daptomycin for the treatment of complicated skin and skin structure infections. Clin Infect Dis 38:1673–1681
Davis SL, McKinnon PS, Hall LM et al (2007) Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes. Pharmacotherapy 27:1611–1618
Falcone M, Russo A, Venditti M, Novelli A, Pai MP (2013) Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 57:1568–1576
Breedt J, Teras J, Gardovskis J et al (2005) Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 49:4658–4666
Corey GR, Wilcox M, Talbot GH et al (2010) Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 51:641–650
Das D, Tulkens PM, Mehra P, Fang E, Prokocimer P (2014) Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary. Clin Infect Dis 58(Suppl 1):S51–S57
Jauregui LE, Babazadeh S, Seltzer E et al (2005) Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 41:1407–1415
Boucher HW, Wilcox M, Talbot GH et al (2014) Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 370:2169–2179
Billeter M, Zervos MJ, Chen AY, Dalovisio JR, Kurukularatne C (2008) Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis 46:577–583
Dunne MW, Puttagunta S, Giordano P et al (2015) A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis 62:545–551
Corey GR, Kabler H, Mehra P et al (2014) Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 370:2180–2190
Corey GR, Good S, Jiang H et al (2015) Single-dose oritavancin versus 7–10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis 60:254–262
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Statement of human and animal rights
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
For this type of study, formal consent is not required.
Rights and permissions
About this article
Cite this article
Falcone, M., Concia, E., Giusti, M. et al. Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs. Intern Emerg Med 11, 637–648 (2016). https://doi.org/10.1007/s11739-016-1450-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-016-1450-6